India-based Gennova Biopharmaceuticals Ltd. announced today that its GEMCOVAC™-19 mRNA vaccine received the Emergency Use Authorization from the office of the Drugs Controller General of India. GEMCOVAC-19 is the first mRNA vaccine developed in India and the only third mRNA vaccine approved for COVID-19 worldwide. The U.S. FDA has already approved two mRNA vaccines for infants, adolescents, and adults.
France-based Valneva SE announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended marketing authorization for Valneva's inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age. The CHMP concluded by consensus after a thorough evaluation that "the data on the vaccine were robust and met the EU criteria for efficacy, safety, and quality."
The U.S. Agency for International Development (USAID), in collaboration with COVAX, announced today they delivered the first two U.S.-facilitated shipments of Pfizer’s Comirnaty COVID-19 vaccines for children in Mongolia (302,400 doses) and Nepal (2.2 million doses).
The Taiwan Food and Drug Administration (FDA) recently granted emergency use authorization for the Novavax COVID-19 vaccine for adults. Local media reported Taiwan FDA experts agreed to approve Novavax's Nuvaxovid™, the first protein-based vaccine per Taiwan's pharmaceutical laws, on June 17, 2022.